Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person ERBB2 TMD/JMD mutants bind pertuzumab

Class:Id	Reaction:9665703
_displayName	ERBB2 TMD/JMD mutants bind pertuzumab
_doRelease	TRUE
_timestamp	2022-11-09 16:55:21
authored	[InstanceEdit:9665478] Orlic-Milacic, Marija, 2019-10-31
compartment	[Compartment:984] extracellular region [Compartment:876] plasma membrane
created	[InstanceEdit:9665710] Orlic-Milacic, Marija, 2019-10-31
disease	[Disease:1500689] cancer
edited	[InstanceEdit:9665760] Orlic-Milacic, Marija, 2019-11-01
entityFunctionalStatus	[EntityFunctionalStatus:9820556] gain_of_function of ERBB2 R678Q:ERBIN:HSP90:CDC37 [plasma membrane]
input	[Complex:9665968] ERBB2 R678Q:ERBIN:HSP90:CDC37 [plasma membrane] [Homo sapiens] [ProteinDrug:9665971] pertuzumab [extracellular region]
isChimeric	FALSE
literatureReference	[LiteratureReference:9666001] Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations
modified	[InstanceEdit:9665729] Orlic-Milacic, Marija, 2019-10-31 [InstanceEdit:9665748] Orlic-Milacic, Marija, 2019-10-31 [InstanceEdit:9665984] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666031] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666039] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666040] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666041] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666042] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666742] Orlic-Milacic, Marija, 2019-11-06 [InstanceEdit:9667512] Orlic-Milacic, Marija, 2019-11-12 [InstanceEdit:9676412] Orlic-Milacic, Marija, 2020-02-13 [InstanceEdit:9817342] Orlic-Milacic, Marija, 2022-09-16 [InstanceEdit:9820558] Orlic-Milacic, Marija, 2022-11-09 [InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
name	ERBB2 TMD/JMD mutants bind pertuzumab
normalReaction	[Reaction:9665726] ERBB2 binds pertuzumab [Homo sapiens]
output	[Complex:9665967] ERBB2 R678Q:pertuzumab:ERBIN:HSP90:CDC37 [plasma membrane] [Homo sapiens]
releaseDate	2020-03-17
reviewed	[InstanceEdit:9666036] Bose, Ron, 2019-10-25 [InstanceEdit:9666034] Krishna, Anagha, 2019-10-25 [InstanceEdit:9666741] Kancha, Rama Krishna, 2019-11-03
reviewStatus	[ReviewStatus:9821382] five stars
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:9665723] R-HSA-9665703.3
summation	[Summation:9665730] ERBB2 R678Q is sensitive to pertuzumab (Pahuja et al. 2018).
(hasEvent)	[Pathway:9665686] Signaling by ERBB2 TMD/JMD mutants [Homo sapiens]
[Change default viewing format]

No pathways have been reviewed or authored by ERBB2 TMD/JMD mutants bind pertuzumab (9665703)